Portal de Periódicos da CAPES

The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C

2018; Impact Journals LLC; Volume: 9; Issue: 30 Linguagem: Inglês

10.18632/oncotarget.25092

1949-2553

Batbold Batsaikhan, Ching‐I Huang, Ming‐Lun Yeh, Chung‐Feng Huang, Nei‐Jen Hou, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang, Jin‐Ching Lee, Chia‐Yen Dai,

Systemic Lupus Erythematosus Research

// Batbold Batsaikhan 1, 2 , Ching-I Huang 3 , Ming-Lun Yeh 3, 4 , Chung-Feng Huang 3, 4, 5 , Nei-Jen Hou 3 , Zu-Yau Lin 3, 4 , Shinn-Cherng Chen 3, 4 , Jee-Fu Huang 3, 4 , Ming-Lung Yu 3, 4 , Wan-Long Chuang 3, 4 , Jin-Ching Lee 5 and Chia-Yen Dai 1, 3, 4, 6 1 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Internal Medicine, Institute of Medical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia 3 Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 4 Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 5 Department of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan 6 Health Management Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan Correspondence to: Chia-Yen Dai, email: daichiayen@gmail.com Keywords: HCV; lipid profiles; triglycerides; FIB4; antiviral treatment Received: December 14, 2017 Accepted: March 22, 2018 Published: April 20, 2018 ABSTRACT Background: Low lipid profile is associated with hepatitis C virus (HCV) infection. Chronic HCV infection is the main cause of liver injury and serum lipid levels during antiviral treatment. We aimed to evaluate the effect of antiviral treatment on the change of lipid profiles during HCV treatment. Methods: Total 863 patients who complete the interferon-based therapy in Kaohsiung Medical University Hospital were included in this study. The lipid profile measured and evaluated in baseline and after 6 months of the treatment. Results: Sustained virological response (SVR) was achieved in 81.2% of all patients. The baseline triglycerides (TG) levels in the SVR group and non SVR groups were similar. The TG levels at 6 months after cessation of the treatment was significantly elevated in SVR group (102.9±57.0 mg/dL, p=0.0001) but did not elevated in non SVR group (94.5±45.6 mg/dL, p=0.690) compared with baseline TG levels. After adjusting patients by four indexes for fibrosis (FIB4) in cut-off point 3.25, serum TG levels significantly increased in low FIB4 group (103.2±57.9 mg/dL, p=0.0001) but not in high FIB4 group (98.1±49.6 mg/dL, p=0.095) after 6 months end of the treatment. Serum TG level was increased greater in patients who had low FIB4 score and patients who achieved SVR (baseline 89.1±34.8 mg/dL; 6 months after treatment 104.3±59.3 mg/dL, paired T test p=0.0001). Conclusion: The clearance of the HCV RNA is the main determinant of the increase of lipids after PegIFN/RBV treatment. However advanced fibrosis also has an effect in increase of lipids after the treatment.